Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist.
WarehouseEU Warehouse
EU Warehouse
Retatrutide
Retatrutide is a clinical-stage triple agonist of the GIP, GLP-1 and glucagon receptors.
Loading …
ELVORA RESEARCH
Description
Randomized phase 2 trials evaluated metabolic endpoints in obesity and type 2 diabetes. The evidence is clinical but still investigational; the FDA states that retatrutide is not approved or established as safe and effective for any condition.
Research sources
External primary and regulatory sources for factual context. Not guidance on use.
Batch documents
Certificates of analysis
Verified batch-specific laboratory reports are linked here without alteration.
View all certificatesNot yet available
No verified COA is currently available for this product.
Continue through the catalogue
